04:46 PM EDT, 09/17/2024 (MT Newswires) -- Kairos Pharma ( KAPA ) said Tuesday it closed its initial public offering of 1.55 million shares at $4 each, raising $6.2 million to fund its early-stage trial in lung cancer and mid-stage trial in prostate cancer for its lead product candidate ENV 105.
Kairos shares debuted on the NYSE American on Monday.